Scott Minick is the President and CEO of BIND Biosciences, Inc. Prior to this, Mr. Minick was a Managing Director of Arch Venture Partners and was instrumental in the startup, development and financing of numerous portfolio companies including BIND, XenoPort, MedVantx, Achaogen, Celula, and Sorbent Therapeutics. From 1995 until 1998, Mr. Minick was director, President and COO of SEQUUS Pharmaceuticals, a public biopharmaceutical company that was acquired by ALZA. He serves as a board director for BIND, Chiasma and Sorbent Therapeutics.
Mr. Minick was formerly an executive at Baxter International, Inc., and Eli Lilly & Company and was Chairman of the Board of California Pacific Medical Center through 2009. He received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University and a B.A. with Honors from the University of California at San Diego.